Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | CA4 | P22748 | 4/20 | 0.37 |
| ▸ | CA6 | P23280 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9731960 | 1.00 | HTT (0.39) | HTTCA1CA2CA4CA6 | |
| SCHEMBL10743083 | 0.99 | HTT (0.41) | HTTCA1CA2CA4CA6 | |
| SCHEMBL24866551 | 0.96 | THRB (0.39) | HTTCA1CA2CA4CA6 | |
| SCHEMBL497184 | 0.96 | THRB (0.39) | HTTCA1CA2CA4CA6 | |
| SCHEMBL24866320 | 0.96 | THRB (0.39) | HTTCA1CA2CA4CA6 | |
| SCHEMBL17339212 | 0.96 | THRB (0.39) | HTTCA1CA2CA4CA6 | |
| SCHEMBL11118139 | 0.84 | PTGS2 (0.42) | HTTCA1CA2CA4CA6 | |
| SCHEMBL19605977 | 0.83 | CTSK (0.44) | GAAALDH1A1KDM4E | |
| SCHEMBL497203 | 0.83 | PTGS1 (0.34) | HTTNPC1RAB9ACYP2D6PTGS1 | |
| SCHEMBL16602948 | 0.82 | PTGS2 (0.42) | HTTNPC1RAB9AGAAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104817471-A | Preparation method for cycloalkanone substituted alanine derivative | ZHEJIANG CHANGMING PHARMACEUTICAL CO LTD | 2015-08-05 | — | — | CN | disclosed |
| US-8105807-B2 | Carbamoylglycine derivatives | DSM IP ASSETS B.V. (NL) | 2012-01-31 | — | — | US | disclosed |
| US-8105807-B2 | Carbamoylglycine derivatives | DSM IP ASSETS B.V. (NL) | 2012-01-31 | — | — | US | disclosed |
| US-8105807-B2 | Carbamoylglycine derivatives | DSM IP ASSETS B.V. (NL) | 2012-01-31 | — | — | US | disclosed |
| EP-2200981-B1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP ASSETS BV (NL) | 2011-12-07 | — | — | EP | disclosed |
| EP-2200981-B1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP ASSETS BV (NL) | 2011-12-07 | — | — | EP | disclosed |
| US-20100221796-A1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2010-09-02 | — | — | US | disclosed |
| US-20100221796-A1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2010-09-02 | — | — | US | disclosed |
| US-20100221796-A1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2010-09-02 | — | — | US | disclosed |
| EP-2200981-A1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP Assets B.V. (NL) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009050041-A1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050041-A1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221796-A1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DNPEP, ACE, PEPD | HTT 4094/4885CA1 3470/4885CA2 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.